-
Something wrong with this record ?
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
G. Günther, F. van Leth, S. Alexandru, N. Altet, K. Avsar, D. Bang, R. Barbuta, G. Bothamley, A. Ciobanu, V. Crudu, M. Danilovits, M. Dedicoat, R. Duarte, G. Gualano, H. Kunst, W. de Lange, V. Leimane, AM. McLaughlin, C. Magis-Escurra, I. Muylle,...
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1997-07-01 to 1 year ago
Freely Accessible Science Journals
from 1997 to 1 year ago
ProQuest Central
from 2003-02-01 to 2019-09-15
Open Access Digital Library
from 1998-01-01
Nursing & Allied Health Database (ProQuest)
from 2003-02-01 to 2019-09-15
Health & Medicine (ProQuest)
from 2003-02-01 to 2019-09-15
Public Health Database (ProQuest)
from 2003-02-01 to 2019-09-15
- MeSH
- Antitubercular Agents therapeutic use MeSH
- Incidence MeSH
- Cohort Studies MeSH
- Humans MeSH
- Tuberculosis, Multidrug-Resistant drug therapy epidemiology MeSH
- Prospective Studies MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
RATIONALE: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. OBJECTIVES: To document the management and treatment outcome in patients with MDR-TB in Europe. METHODS: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients with MDR-TB in Europe. Treatment outcomes were compared by World Health Organization and alternative simplified definitions by the Tuberculosis Network European Trialsgroup (TBNET). MEASUREMENTS AND MAIN RESULTS: A total of 380 patients with MDR-TB were recruited and followed up between 2010 and 2014 in 16 European countries. Patients in high-incidence countries compared with low-incidence countries were treated more frequently with standardized regimen (83.2% vs. 9.9%), had delayed treatment initiation (median, 111 vs. 28 d), developed more additional drug resistance (23% vs. 5.8%), and had increased mortality (9.4% vs. 1.9%). Only 20.1% of patients using pyrazinamide had proven susceptibility to the drug. Applying World Health Organization outcome definitions, frequency of cure (38.7% vs. 9.7%) was higher in high-incidence countries. Simplified outcome definitions that include 1 year of follow-up after the end of treatment showed similar frequency of relapse-free cure in low- (58.3%), intermediate- (55.8%), and high-incidence (57.1%) countries, but highest frequency of failure in high-incidence countries (24.1% vs. 14.6%). CONCLUSIONS: Conventional standard MDR-TB treatment regimens resulted in a higher frequency of failure compared with individualized treatments. Overall, cure from MDR-TB is substantially more frequent than previously anticipated, and poorly reflected by World Health Organization outcome definitions.
33 German Center for Infection Research Borstel Germany
Asklepios Klinik Gauting Gauting Germany
Balti Municipal Hospital Balti Republic of Moldova
Homerton University Hospital London United Kingdom
Hospital Universitari Vall d'Hebron Research Institute IDIAP Jordi Gol Barcelona Spain
Institute of Phthisiopneumology Chisinau Republic of Moldova
Marius Nasta Institut Bucharest Romania
National Institute for Health Development Tallinn Estonia
National Institute for Infectious Diseases L Spallanzani Rome Italy
Otto Wagner Hospital Vienna Austria
Queen Mary University London United Kingdom
Republican Research and Practical Centre for Pulmonology and Tuberculosis Minsk Belarus
Riga East University Hospital Tuberculosis and Lung Diseases Centre Riga Latvia
St James's Hospital Dublin Ireland
Statens Serum Institut Copenhagen Denmark
Tartu University Lung Hospital Tartu Estonia
Thomayer University Hospital Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035366
- 003
- CZ-PrNML
- 005
- 20191010100338.0
- 007
- ta
- 008
- 191007s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1164/rccm.201710-2141OC $2 doi
- 035 __
- $a (PubMed)29509468
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Günther, Gunar $u 1 Research Center Borstel, Clinical Infectious Diseases, German Center for Infection Research, Borstel, Germany. 2 Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia.
- 245 10
- $a Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries / $c G. Günther, F. van Leth, S. Alexandru, N. Altet, K. Avsar, D. Bang, R. Barbuta, G. Bothamley, A. Ciobanu, V. Crudu, M. Danilovits, M. Dedicoat, R. Duarte, G. Gualano, H. Kunst, W. de Lange, V. Leimane, AM. McLaughlin, C. Magis-Escurra, I. Muylle, V. Polcová, C. Popa, R. Rumetshofer, A. Skrahina, V. Solodovnikova, V. Spinu, S. Tiberi, P. Viiklepp, C. Lange, for TBNET,
- 520 9_
- $a RATIONALE: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. OBJECTIVES: To document the management and treatment outcome in patients with MDR-TB in Europe. METHODS: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients with MDR-TB in Europe. Treatment outcomes were compared by World Health Organization and alternative simplified definitions by the Tuberculosis Network European Trialsgroup (TBNET). MEASUREMENTS AND MAIN RESULTS: A total of 380 patients with MDR-TB were recruited and followed up between 2010 and 2014 in 16 European countries. Patients in high-incidence countries compared with low-incidence countries were treated more frequently with standardized regimen (83.2% vs. 9.9%), had delayed treatment initiation (median, 111 vs. 28 d), developed more additional drug resistance (23% vs. 5.8%), and had increased mortality (9.4% vs. 1.9%). Only 20.1% of patients using pyrazinamide had proven susceptibility to the drug. Applying World Health Organization outcome definitions, frequency of cure (38.7% vs. 9.7%) was higher in high-incidence countries. Simplified outcome definitions that include 1 year of follow-up after the end of treatment showed similar frequency of relapse-free cure in low- (58.3%), intermediate- (55.8%), and high-incidence (57.1%) countries, but highest frequency of failure in high-incidence countries (24.1% vs. 14.6%). CONCLUSIONS: Conventional standard MDR-TB treatment regimens resulted in a higher frequency of failure compared with individualized treatments. Overall, cure from MDR-TB is substantially more frequent than previously anticipated, and poorly reflected by World Health Organization outcome definitions.
- 650 _2
- $a antituberkulotika $x terapeutické užití $7 D000995
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a multirezistentní tuberkulóza $x farmakoterapie $x epidemiologie $7 D018088
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a van Leth, Frank $u 3 Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 4 Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
- 700 1_
- $a Alexandru, Sofia $u 5 Institute of Phthisiopneumology, Chisinau, Republic of Moldova.
- 700 1_
- $a Altet, Neus $u 6 Hospital Universitari Vall d'Hebron, Research Institute-IDIAP Jordi Gol, Barcelona, Spain.
- 700 1_
- $a Avsar, Korkut $u 7 Asklepios Klinik Gauting, Gauting, Germany.
- 700 1_
- $a Bang, Didi $u 8 Statens Serum Institut, Copenhagen, Denmark.
- 700 1_
- $a Barbuta, Raisa $u 9 Balti Municipal Hospital, Balti, Republic of Moldova.
- 700 1_
- $a Bothamley, Graham $u 10 Homerton University Hospital, London, United Kingdom.
- 700 1_
- $a Ciobanu, Ana $u 5 Institute of Phthisiopneumology, Chisinau, Republic of Moldova.
- 700 1_
- $a Crudu, Valeriu $u 5 Institute of Phthisiopneumology, Chisinau, Republic of Moldova. 11 National Tuberculosis Reference Laboratory, Chisinau, Republic of Moldova.
- 700 1_
- $a Danilovits, Manfred $u 12 Tartu University Lung Hospital, Tartu, Estonia.
- 700 1_
- $a Dedicoat, Martin $u 13 Heart of England Foundation Trust, Birmingham, United Kingdom. 14 University of Warwick, Coventry, United Kingdom.
- 700 1_
- $a Duarte, Raquel $u 15 EpiUnit, Institute of Public Health, Porto University, Porto, Portugal. 16 Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Porto, Portugal.
- 700 1_
- $a Gualano, Gina $u 17 National Institute for Infectious Diseases "L, Spallanzani," Rome, Italy.
- 700 1_
- $a Kunst, Heinke $u 18 Queen Mary University, London, United Kingdom.
- 700 1_
- $a de Lange, Wiel $u 19 University of Groningen, University Medical Center Groningen, Tuberculosis Centre Beatrixoord, Haren, the Netherlands.
- 700 1_
- $a Leimane, Vaira $u 20 Riga East University Hospital, Tuberculosis and Lung Diseases Centre, Riga, Latvia.
- 700 1_
- $a McLaughlin, Anne-Marie $u 21 St. James's Hospital, Dublin, Ireland.
- 700 1_
- $a Magis-Escurra, Cecile $u 22 Radboud University Medical Centre-TB Expert Centre UCCZ Dekkerswald, Nijmegen-Groesbeek, the Netherlands.
- 700 1_
- $a Muylle, Inge $u 23 University Medical Center St. Pieter, Brussels, Belgium.
- 700 1_
- $a Polcová, Veronika $u 24 Thomayer University Hospital, Prague, Czech Republic.
- 700 1_
- $a Popa, Cristina $u 25 Marius-Nasta-Institut, Bucharest, Romania.
- 700 1_
- $a Rumetshofer, Rudolf $u 26 Otto Wagner Hospital, Vienna, Austria.
- 700 1_
- $a Skrahina, Alena $u 27 Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
- 700 1_
- $a Solodovnikova, Varvara $u 27 Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
- 700 1_
- $a Spinu, Victor $u 25 Marius-Nasta-Institut, Bucharest, Romania.
- 700 1_
- $a Tiberi, Simon $u 28 Ospedale Eugenio Morelli Reference Hospital for MDR and HIV-TB, Sondalo, Italy. 29 Barts Health NHS Trust, London, United Kingdom.
- 700 1_
- $a Viiklepp, Piret $u 30 National Institute for Health Development, Tallinn, Estonia.
- 700 1_
- $a Lange, Christoph $u 1 Research Center Borstel, Clinical Infectious Diseases, German Center for Infection Research, Borstel, Germany. 31 International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany. 32 Department of Medicine, Karolinska Institute, Stockholm, Sweden; and. 33 German Center for Infection Research, Borstel, Germany.
- 710 2_
- $a for TBNET
- 773 0_
- $w MED00000297 $t American journal of respiratory and critical care medicine $x 1535-4970 $g Roč. 198, č. 3 (2018), s. 379-386
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29509468 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191010100757 $b ABA008
- 999 __
- $a ok $b bmc $g 1452026 $s 1073916
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 198 $c 3 $d 379-386 $e 20180801 $i 1535-4970 $m American journal of respiratory and critical care medicine $n Am J Respir Crit Care Med $x MED00000297
- LZP __
- $a Pubmed-20191007
